Study: 123I-mIBG imaging helps identify risk of arrhythmia

11/22/2009 | Doctor's Guide

A follow-up study to the ADMIRE-HF trial showed that cardiac imaging using iobenguane I-123 helps pinpoint heart-failure patients that have a low risk of fatal arrhythmic events and a higher-than-normal fatal and nonfatal arrhythmia risk. "We found that reduced myocardial sympathetic innervation on 123I-mIBG imaging is a strong and independent predictor of mortality in patients with advanced congestive heart failure," the study's lead investigator said.

View Full Article in:

Doctor's Guide

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations